A Phase I/II Randomized Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 02 Aug 2017
At a glance
- Drugs Cancer vaccine (Primary) ; Cancer vaccine (Primary) ; Rintatolimod (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 28 Jul 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Mar 2018.
- 10 Jun 2017 Biomarkers information updated
- 21 Jun 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Mar 2017.